Literature DB >> 29566113

Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer-The New Standard of Care?

Theodore S Hong1, David P Ryan2.   

Abstract

Mesh：

Year:  2018        PMID： 29566113     DOI： 10.1001/jamaoncol.2018.0070

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  8 in total

1.  Cost-minimisation analysis of rectal cancer neoadjuvant chemoradiotherapy based on fluoropyrimidines (capecitabine versus 5-fluorouracil).

Authors:  Sergio Marin; Laia Pérez-Cordón; Francesc Salvà; Marcel la Camps; Lluís Campins; Pilar Lianes
Journal:  Eur J Hosp Pharm       Date:  2020-03-27

Review 2.  Recent advances of neoadjuvant chemoradiotherapy in rectal cancer: Future treatment perspectives.

Authors:  Kimihiro Yamashita; Takeru Matsuda; Hiroshi Hasegawa; Junko Mukohyama; Akira Arimoto; Tomoko Tanaka; Masashi Yamamoto; Yoshiko Matsuda; Shingo Kanaji; Tetsu Nakamura; Yasuo Sumi; Satoshi Suzuki; Yoshihiro Kakeji
Journal:  Ann Gastroenterol Surg       Date:  2018-10-24

3.  Comparative survival analysis of preoperative and postoperative radiotherapy in stage II-III rectal cancer on the basis of long-term population data.

Authors:  Yu Jin Lim; Youngkyong Kim; Moonkyoo Kong
Journal:  Sci Rep       Date:  2018-11-21       Impact factor: 4.379

4.  The Impact of Primary Tumor and Locoregional Metastatic Lymph Node SUVmax on Predicting Survival in Patients with Rectal Cancer.

Authors:  Göksel Alçın; Yasemin Şanlı; Gülçin Yeğen; Esra Kaytan Sağlam; Tevfik Fikret Çermik
Journal:  Mol Imaging Radionucl Ther       Date:  2020-04-29

5.  Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy.

Authors:  Andrea Cercek; Gustavo Dos Santos Fernandes; Campbell S Roxburgh; Karuna Ganesh; Shu Ng; Francisco Sanchez-Vega; Rona Yaeger; Neil H Segal; Diane L Reidy-Lagunes; Anna M Varghese; Arnold Markowitz; Chao Wu; Bryan Szeglin; Charles-Etienne Gabriel Sauvé; Erin Salo-Mullen; Christina Tran; Zalak Patel; Asha Krishnan; Kaitlyn Tkachuk; Garrett M Nash; Jose Guillem; Philip B Paty; Jinru Shia; Nikolaus Schultz; Julio Garcia-Aguilar; Luis A Diaz; Karyn Goodman; Leonard B Saltz; Martin R Weiser; J Joshua Smith; Zsofia K Stadler
Journal:  Clin Cancer Res       Date:  2020-03-06       Impact factor: 12.531

6.  Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer.

Authors:  Susan G R McDuff; Karin M Hardiman; Peter J Ulintz; Aparna R Parikh; Hui Zheng; Daniel W Kim; Jochen K Lennerz; Mehlika Hazar-Rethinam; Emily E Van Seventer; Isobel J Fetter; Brandon Nadres; Christine E Eyler; David P Ryan; Colin D Weekes; Jeffrey W Clark; James C Cusack; Lipika Goyal; Andrew X Zhu; Jennifer Y Wo; Lawrence S Blaszkowsky; Jill Allen; Ryan B Corcoran; Theodore S Hong
Journal:  JCO Precis Oncol       Date:  2021-01-12

7.  Comparing outcomes following total neoadjuvant therapy and following neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer.

Authors:  Shaoyu Zhu; N Patrik Brodin; Keara English; Nitin Ohri; Jennifer W Chuy; Lakshmi N Rajdev; Rahul Narang; Shalom Kalnicki; Chandan Guha; Madhur K Garg; Rafi Kabarriti
Journal:  EClinicalMedicine       Date:  2019-10-22

8.  Cost-effectiveness of Total Neoadjuvant Therapy With Short-Course Radiotherapy for Resectable Locally Advanced Rectal Cancer.

Authors:  Re-I Chin; Ebunoluwa E Otegbeye; Kylie H Kang; Su-Hsin Chang; Scott McHenry; Amit Roy; William C Chapman; Lauren E Henke; Shahed N Badiyan; Katrina Pedersen; Benjamin R Tan; Sean C Glasgow; Matthew G Mutch; Pamela P Samson; Hyun Kim
Journal:  JAMA Netw Open       Date:  2022-02-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.